Investor Overview

Corporate Profile
Verastem, Inc. (NASDAQ:VSTM) is a biopharmaceutical company focused on discovering and developing drugs to improve outcomes for patients with cancer. Verastem’s product candidates seek to treat cancer by targeting malignant cells both directly and through modulation of the tumor microenvironment. The Company is currently developing duvelisib, a dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, which has successfully met its primary endpoint in a Phase 3 registration trial in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and a Phase 2 study in refractory indolent Non-Hodgkin’s Lymphoma (iNHL). Verastem plans to share these clinical data with the U.S. Food and Drug Administration (FDA) with the goal of filing a New Drug Application (NDA) with the FDA during the first half of 2018. Other clinical product candidates include focal adhesion kinase (FAK) inhibitors defactinib. Defactinib is currently being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of several different cancer types, including pancreatic, ovarian and non-small cell lung cancer, and mesothelioma.
Stock Quote
VSTM (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 0.3 (5.83%)
Data as of 09/21/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News More >>
09/06/17Verastem Expands Duvelisib Development Program to Include Peripheral T-Cell Lymphoma
Duvelisib Receives Fast Track Designation from FDA in PTCL; Company to Initiate a Phase 2 Clinical Trial by Year End 2017 Former Chief Marketing Officer, Lilly Oncology, Brian Stuglik Joins the Company’s Board of Directors Conference Call Scheduled for Today at 8:00 AM ET BOSTON--(BUSINESS WIRE)--Sep. 6, 2017-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life ... 
Printer Friendly Version
09/06/17Verastem Announces Positive Top-line Data from the Pivotal Phase 3 DUO™ Study in Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
The Primary Outcome of Progression Free Survival (PFS) via Independent Review Committee (IRC) in the Intent to Treat (ITT) Population Significantly Favored Duvelisib Monotherapy Over Ofatumumab (Median PFS of 13.3 versus 9.9 Months, Respectively; Hazard Ratio (HR) of 0.52, p<0.0001) Similar Efficacy Benefit for Duvelisib Monotherapy Over Ofatumumab for Patients with 17p Deletion (Median PFS of 12.7 versus 9.0 Months, Respectively; HR of... 
Printer Friendly Version
08/08/17Verastem Reports Second Quarter 2017 Financial Results
Company Expects to Report Top-line Data from Phase 3 DUO™ Study in Late Summer 2017 BOSTON--(BUSINESS WIRE)--Aug. 8, 2017-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today reported financial results for the second quarter ended June 30, 2017 and provided an overview of certain corporate developments. “The second quarter of 2017 was marked b... 
Printer Friendly Version
07/25/17Verastem Publishes Scientific Data Highlighting Potential Role of FAK Inhibition in Pancreatic and Breast Cancer
Preclinical Data Supportive of Ongoing Clinical Collaboration Trials Evaluating FAK Inhibition in Combination with Chemotherapeutic and Immunotherapeutic Agents BOSTON--(BUSINESS WIRE)--Jul. 25, 2017-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced scientific findings from studies evaluating focal adhesion kinase (FAK) inhibition in precl... 
Printer Friendly Version
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Verastem Inc posts new information to the site. Just enter your e-mail address and click Submit.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.